X0306 4 2018-08-23 0 0001411690 BioNano Genomics, Inc BNGO 0001747536 Zhou Quan C/O BIONANO GENOMICS, INC. 9640 TOWNE CENTRE DRIVE, SUITE 100 SAN DIEGO CA 92121 1 0 1 0 Common Stock 2018-08-23 4 C 0 199653 A 199653 I By entities affiliated with LC Fund VI, L.P. Common Stock 2018-08-23 4 C 0 150550 A 350203 I By entities affiliated with LC Fund VI, L.P. Common Stock 2018-08-23 4 C 0 637984 A 988187 I By entities affiliated with LC Fund VI, L.P. Common Stock 2018-08-23 4 C 0 784728 A 1772915 I By LC Healthcare Fund I, L.P. Common Stock 2018-08-23 4 C 0 1134000 A 2906915 I By Rosy Shine Limited Series C Convertible Preferred Stock 2018-08-23 4 C 0 8545184 0.00 D Common Stock 199653 0 I By entities affiliated with LC Fund VI, L.P. Series D Convertible Preferred Stock 2018-08-23 4 C 0 6443565 0.00 D Common Stock 150550 0 I By entities affiliated with LC Fund VI, L.P. Series D-1 Convertible Preferred Stock 2018-08-23 4 C 0 27305708 0.00 D Common Stock 637984 0 I By entities affiliated with LC Fund VI, L.P. Automatic conversion, in connection with the Issuer's initial public offering, of preferred stock into shares of common stock on a 1-for-42.8 basis. The shares have no expiration date. The shares are held as follows: 191,667 shares held by LC Fund VI, L.P. ("LC Fund") and 7,986 shares held by LC Parallel Fund VI, L.P. ("Parallel Fund") LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. The shares are held as follows: 143,533 shares held by LC Fund and 7,017 shares held by Parallel Fund. LC Fund and Parallel Fund are controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. The shares are held as follows: 91,700 shares held by LC Fund, 540,631 shares held by Parallel Fund and 5,653 shares held by LC Healthcare Fund I, L.P. ("Healthcare Fund"). LC Fund, Parallel Fund and Healthcare Fund are controlled and managed by Legend Capital, a limited liability Chinese company ("Legend Capital"). The Reporting Person is an Executive Director of Legend Capital and disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. Represents the conversion of an outstanding convertible promissory note in the principal amount of $3,460,000, plus $144,846.03 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $6.125 per share. Healthcare Fund is controlled and managed by Legend Capital, a limited liability Chinese company. The Reporting Person is an Executive Director of Legend Capital. The Reporting Person disclaims beneficial ownership with respect to these securities, except to the extent of his pecuniary interest therein. Represents the conversion of an outstanding convertible promissory note in the principal amount of $5,000,000, plus $209,315.07 accrued interest, into shares of the Issuer's common stock upon closing of the Issuer's initial public offering at a conversion price of $6.125 per share. Rosy Shine Limited is ultimately controlled and managed by Legend Holdings, a limited liability Chinese joint stock company listed on a Stock Exchange of Hong Kong (3396), which is controlled by its board of directors. The board of directors of Legend Holdings has sole voting and investment power over the shares held by Rosy Shine Limited. None of the members of the board of directors has individual voting or investment power with respect to such shares and each disclaims beneficial ownership of such shares. /s/ Heather Adams, Attorney-in-fact 2018-08-27